Gong Zhi-Jun, Ren Jing-Qing, Kong Gang, Qing Du-Ju, Liu Hong, Liang Yong-Quan
Department of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, Guangdong, 529030, PR China.
Ai Zheng. 2007 Dec;26(12):1350-3.
BACKGROUND & OBJECTIVE: Recently, some scholars advocate perioperative chemotherapy for colorectal cancer. This study aimed to investigate the impact of perioperative chemotherapy on the prognosis of colorectal cancer.
From Aug. 2001 to Aug. 2003, 167 patients with Dukes'B or C colorectal cancer were randomized into two groups: 82 in trial group received perioperative chemotherapy using 5-fluorouracil (5-FU), while 85 in control group received no perioperative chemotherapy. All patients received adjuvant chemotherapy of 5-FU/leucovorin regimen. The adverse events, recurrence rate and survival rate were compared between these two groups.
There was no difference in adverse events between the two groups. The overall recurrence rate was 42.5%û it was significantly lower in trial group than in control group (34.6% vs. 49.4%, P=0.038). The overall 1-, 3-, and 4-year survival rates were 97.6%, 74.7% and 61.8%û they were significantly higher in trial group than in control group (100% vs. 95.3%, 82.7% vs. 67.1%, and 69.1% vs. 54.8%, P=0.046).
Perioperative chemotherapy can improve the prognosis of colorectal cancer.
近期，一些学者主张对结直肠癌患者进行围手术期化疗。本研究旨在探讨围手术期化疗对结直肠癌预后的影响。
2001年8月至2003年8月，将167例 Dukes'B 或 C 期结直肠癌患者随机分为两组：试验组82例，采用5-氟尿嘧啶（5-FU）进行围手术期化疗；对照组85例，未进行围手术期化疗。所有患者均接受5-FU/亚叶酸钙方案的辅助化疗。比较两组的不良事件、复发率和生存率。
两组不良事件无差异。总复发率为42.5%，试验组显著低于对照组（34.6%对49.4%，P = 0.038）。1年、3年和4年总生存率分别为97.6%、74.7%和61.8%，试验组显著高于对照组（100%对95.3%，82.7%对67.1%，69.1%对54.8%，P = 0.046）。
围手术期化疗可改善结直肠癌的预后。
